ISSN 2410-955X - An International Biannual Journal
Immunoediting and tumor neoantigens that can impact the efficacy of immunotherapies
Katyayani Tatiparti, Mohd. Ahmar Rauf*
Department of Pharmaceutical sciences, Wayne state University, Detroit, MI, USA
Immunoediting is by far the most serious challenge in the immunotherapies that are on the rise for Glioblastoma Multiforme (GBM). However, it is a double-edged sword because this process can be suppressive of the tumor too. Personalized medicine will succeed only if there are effective methods in place to address this challenge. A thorough understanding of the host immune system and the tumor cells heterogeneity and their mutual interactions is necessary. There is a lot of research being pursued in this direction. So far, the main aspect identified for developing immunotherapy for GBM is finding the balance between the immunoediting and the use of neoantigens for neoantigen-directed T-cell therapies.